Evidence map›Paper›PMID 31413633›Full record

ArticleCancer management and research2019

Prognostic values of baseline, interim and end-of therapy

Yeye Zhou, Zixuan Zhao, Jihui Li, Bin Zhang, Shibiao Sang, Yiwei Wu, Shengming Deng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Semiquantitative 2-[Frontiers in medicine · 2024
    Review
  12. Article
  13. Prognostic value of interimAnnals of hematology · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Prognostic Values of BaselineBioMed research international · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yeye Zhou *Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Zixuan Zhao *Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Jihui LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Bin ZhangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Shibiao SangDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Yiwei Wu *Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.
Shengming DengDepartment of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn the present study, we aimed to investigate the role of baseline, interim and end-of treatment positron emission tomography/computed tomography (PET/CT) in assessing the prognosis of follicular lymphoma (FL).

methodsA total of 84 FL patients were retrospectively analyzed in this study. Baseline (n=59), interim (n=24, after 2-4 cycles) and end-of treatment (n=43) PET/CT images were re-evaluated, and baseline maximum standardized uptake value (SUV

resultsThe 2-year progression-free survival (PFS) of the high- and low-TLG groups was 57.14% and 95.56%, respectively (

conclusionOur findings indicated that the baseline TLG and E-PET results were significantly associated with prognosis in patients with FL.

Indexed as

D-5PSfollicular lymphomaIHPMTVPET/CTTLG

Identifiers

PMID31413633
PMCPMC6662523

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.